Michele Guida1, Luca G Campana2,3, Pietro Curatolo4, Sabino Strippoli1, Antonio Bonadies5, Gretha Grilz6, Carlo Cabula7, Roberta Rotunno4, Stefania Bucher5, Nicola Solari8, Antonio Santoriello9, Sara Valpione3,10, Carlo R Rossi2,3. 1. Medical Oncology Unit, Istituto dei Tumori, Bari, Italy. 2. Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. 3. Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy. 4. Department of Dermatology and Plastic Surgery, La Sapienza University, Roma, Italy. 5. Plastic Surgery Unit, San Gallicano Dermatologic Institute IRCCS IFO, Roma, Italy. 6. Breast Surgery Unit, Città della salute e della scienza di Torino, Italy. 7. Oncologic Surgery, Ospedale Oncologico A. Businco, Cagliari, Italy. 8. Surgical Unit 1, San Martino IST-IRCCS, Genova, Italy. 9. Dipartimento di chirurgia generale e specialistica II Università di Napoli, Italy. 10. Medical Oncology, The Christie NHS Trust, Manchester, United Kingdom.
Abstract
BACKGROUND: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. METHODS: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. RESULTS: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). CONCLUSIONS: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246-253.
BACKGROUND:Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. METHODS: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. RESULTS: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). CONCLUSIONS: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246-253.
Authors: Armando De Virgilio; Massimo Ralli; Lucia Longo; Patrizia Mancini; Giuseppe Attanasio; Francesca Atturo; Marco De Vincentiis; Antonio Greco Journal: Oncol Lett Date: 2018-07-12 Impact factor: 2.967
Authors: Sophie E R Horbach; Albert Wolkerstorfer; Daniel Martijn de Bruin; Sanne M Jansen; Chantal M A M van der Horst Journal: BMJ Open Date: 2017-11-14 Impact factor: 2.692